Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform

ACCESSWIRE11-14

Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483875152?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9bov66OKbErabpVlcYzNfA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4ffd0ea9ae13cf2010e5589cbaefbd3f","is_english":true,"pubTime":"2024-11-14 19:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483875152","market":"us","top_or_hot":-1,"title":"Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform","media":"ACCESSWIRE","content":"<div>\n<p>Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients\nANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) (\"...</p>\n\n<a href=\"https://finance.yahoo.com/news/zomedica-launches-quantitative-insulin-assay-113000912.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zomedica-launches-quantitative-insulin-assay-113000912.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients\nANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) (\"...</p>\n\n<a href=\"https://finance.yahoo.com/news/zomedica-launches-quantitative-insulin-assay-113000912.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4232","symbol_name":"货物陆运","start_time":0,"source_url":"https://finance.yahoo.com/news/zomedica-launches-quantitative-insulin-assay-113000912.html","article_id":"2483875152","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9bov66OKbErabpVlcYzNfA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4ffd0ea9ae13cf2010e5589cbaefbd3f"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483875152","pubTimestamp":1731583800,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients. ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp.  , a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform.T.J. Barclay, DVM, a Zomedica Professional Services Veterinarian, commented, \"Early identification of horses with insulin dysregulation is key in preventing hyperinsulinemia-associated laminitis. The TRUFORMA insulin assay delivers that critical information within minutes. The combination of TRUFORMA's insulin and eACTH assays can provide the veterinarian with a complete understanding of the patient's laminitis risk, allowing treatment decisions to be made on the spot.\". Zomedica is a leading equine and companion animal healthcare company dedicate","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4232":"货物陆运","BK4022":"陆运","R":"瑞德系统","ZOM":"Zomedica Pharmaceuticals Corp.","BK4082":"医疗保健设备"},"translate_title":"Zomedica在TRUFORMA(R)平台上推出马血浆胰岛素定量检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"R":1,"ZOM":1},"content_text":"Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients\nANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) (\"Zomedica\" or the \"Company\"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform.\nVeterinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dysfunction (PPID), with prevalence reported between 18-27% of ponies and horses. Left untreated, laminitis, which can lead to euthanasia, is a consequence of both EMS and PPID.\nThe TRUFORMA Insulin assay offers quantitative detection of insulin levels in equine plasma, with results available in just 18 minutes. This rapid turnaround enables veterinarians to diagnose and monitor insulin dysregulation in horses quickly, eliminating the need for reference laboratory wait times and allowing for immediate treatment decisions. The assay is designed for both in-clinic and stall-side use, providing flexibility for various clinical settings. Importantly, Zomedica offers this advanced diagnostic capability with no capital outlay or monthly minimums from veterinary practices.\nKatarzyna Dembek DVM, PhD, DACVIM, Assistant Professor of Equine Internal Medicine at North Carolina State University, stated, \"Accurate diagnosis and monitoring of insulin dysregulation is crucial when making treatment decisions for horses with equine metabolic syndrome. Having the TRUFORMA insulin assay available at point-of-care allows those decisions to be made on the spot, rather than waiting days for results from a reference lab.\"\nT.J. Barclay, DVM, a Zomedica Professional Services Veterinarian, commented, \"Early identification of horses with insulin dysregulation is key in preventing hyperinsulinemia-associated laminitis. The TRUFORMA insulin assay delivers that critical information within minutes. The combination of TRUFORMA's insulin and eACTH assays can provide the veterinarian with a complete understanding of the patient's laminitis risk, allowing treatment decisions to be made on the spot.\"\nThe TRUFORMA Insulin assay for equine plasma may be ordered now from Zomedica. For more information, visit www.zomedica.com.\nAbout Zomedica\nZomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.\nFollow Zomedica\n\nEmail Alerts: http://investors.zomedica.com\nLinkedIn: https://www.linkedin.com/company/zomedica\nFacebook: https://m.facebook.com/zomedica\nX (formerly Twitter): https://twitter.com/zomedica\nInstagram: https://www.instagram.com/zomedica_inc\n\nCautionary Note Regarding Forward-Looking Statements\nExcept for statements of historical fact, this news release contains certain \"forward-looking information\" or \"forward-looking statements\" (collectively, \"forward-looking information\") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as \"plan\", \"expect\", \"project\", \"intend\", \"believe\", \"anticipate\", \"estimate\" and other similar words, or statements that certain events or conditions \"may\" or \"will\" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.\nForward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.\nOur forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance of the TRUFORMA platform or equine insulin assay; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.\nThe forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.\nInvestor Relations Contact:\nZomedica Investor Relationsinvestors@zomedica.com1-734-369-2555\nSOURCE: Zomedica Corp.\n\nView the original \npress release on accesswire.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483875152"}